Symptom & Side Effect Management Resource Guides
In collaboration with top melanoma oncology specialists, AIM has created comprehensive and current information on the side effects of melanoma treatments approved by the U.S. Food and Drug Administration. Recognizing that melanoma and its treatments impact individuals differently, gaining knowledge on managing your care and side effects is crucial for your well-being.
To access detailed guides for managing side effects, please select the drug(s) you’re interested in. These downloadable documents are designed to help you identify and cope with side effects effectively. We recommend bringing these documents to your next healthcare appointment to discuss them with your provider.
- BRAFTOVI™ (encorafenib)/MEKTOVI® (binimetinib)
- COTELLIC® (cobimetinib)/ZELBORAF® (vemurafenib)
- IMLYGIC® (talimogene laherparepvec; T-VEC)
- KEYTRUDA® (pembrolizumab)
- KIMMTRAK® (tebentafusp-tebn)
- OPDIVO® (nivolumab)
- OPDIVO® (nivolumab)/YERVOY® (ipilimumab)
- OPDUALAG™ (nivolumab) (relatlimab)
- TAFINLAR® (dabrafenib)/MEKINIST® (trametinib)
- YERVOY® (ipilimumab)